Sign in

    Dina Ramadan

    Vice President and equity research analyst at Bank of America

    Dina Ramadan is a Vice President and equity research analyst at Bank of America, specializing in covering the European business services and support services sectors. She focuses on analyzing major listed companies such as Sodexo, Compass Group, ISS, and G4S, generating actionable insights for institutional investors. Since joining Bank of America in 2017, she has built a reputation for analytical rigor and detailed financial modeling, which has contributed to a solid track record of published recommendations and sector forecasts. Dina holds multiple securities licenses including FINRA Series 7 and 63, and is known for her expertise in sector trends and client engagement across EMEA markets.

    Dina Ramadan's questions to Travere Therapeutics (TVTX) leadership

    Dina Ramadan's questions to Travere Therapeutics (TVTX) leadership • Q3 2024

    Question

    Dina Ramadan from Bank of America asked about the broader market opportunity for FILSPARI in FSGS, including whether it requires market building and the potential challenges for a new therapy in a space with no approved treatments.

    Answer

    Chief Commercial Officer Peter Heerma estimated the addressable U.S. market at 15,000 to 30,000 patients, noting it's the same prescriber base as IgAN, which should lead to rapid uptake. Chief Medical Officer Dr. Jula Inrig added that there is a high unmet need for effective, non-immunosuppressive therapies. President and CEO Dr. Eric Dube concluded that they expect to become the leader and new standard of care.

    Ask Fintool Equity Research AI